Metabolic medicines
AICAR
An AMPK-related research compound whose mouse endurance findings do not establish a human exercise benefit.
Animal endurance research; negative cardiac-surgery trial
Also known as: acadesine
Practical use
Reviewed practical notes
- Check the population
- Keep mouse endurance separate from clinical treatment in cardiac-surgery patients.
- Read the actual endpoint
- A change in metabolic signaling is not a measurement of human fitness.
- Verify identity
- A product name alone does not establish the molecule, purity or formulation tested in a paper.
Overview
AICAR is a research name associated with acadesine. It is studied in cellular energy signaling, including AMP-activated protein kinase (AMPK). Activating an energy-sensing pathway is not equivalent to reproducing the many adaptations produced by exercise.
Risks and limitations
The cited human study was conducted around cardiac surgery under clinical supervision. It does not establish safety for healthy people using products marketed for endurance. Chemical identity, formulation and the clinical purpose all matter when comparing that research with a consumer claim.
How to read this
The mouse and human studies address different questions. The mouse result motivates research; the much larger surgery trial does not demonstrate a performance benefit and did not improve its own primary clinical outcome.
Research explained
Mouse endurance experiment
Who was studied
Sedentary mice in a four-week pharmacology experiment.
What was found
The investigators reported increased running endurance and changes in metabolic gene expression with AICAR.
What it cannot establish
An animal treadmill result cannot establish improved endurance, training adaptation or long-term safety in people. The separate PPAR drug in this paper was GW1516, not GW0742.
Read the original studyRED-CABG clinical trial
Who was studied
3,080 adults randomized before coronary bypass surgery; the study stopped early for futility.
What was found
The 28-day composite of death, nonfatal stroke or severe ventricular dysfunction occurred in 5.1% with acadesine and 5.0% with placebo.
What it cannot establish
A perioperative cardiac endpoint is unrelated to healthy athletic enhancement. Early stopping and the specific patient setting bound the interpretation.
Read the original studyMatch the chemical and the experiment
PubChem links acadesine with the AICAR research name. That identity check does not authenticate a commercial product. A paper about another energy-pathway compound cannot be substituted just because the compounds share an exercise-mimetic label.
Supporting sourceSources
PubChem acadesine identity record
Sources checked 2026-10-01.
General education; not a personal treatment plan.